arrow
N

Najjar, Yana

ut md anderson cancer center
H指数:0
被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NEOADJUVANT VIDUTOLIMOD (VIDU) AND NIVOLUMAB (NIVO) RESULTS IN MPR AND IMMUNE ACTIVATION IN HIGH-RISK RESECTABLE MELANOMA (MEL): FINAL PHASE II CLINICAL TRIAL RESULTS
2022-12-083
OA
GENERALIZABILITY OF PREDICTIVE VERSUS PROGNOSTIC INDICATORS FROM PUBLISHED TRANSCRIPTOMIC ASSOCIATIONS WITH TUMOR RESPONSE TO IMMUNE CHECKPOINT INHIBITION
2022-11-070
OA
PRELIMINARY CLINICAL EXPERIENCE WITH XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
2021-11-1014
OA
PRELIMINARY SAFETY, PHARMACOKINETICS/PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
2020-12-107
OAAI
GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCER
2020-12-100
PREAI